Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C

  • Rashed, Yasser K. (Department of Pediatric Hepatology, National Liver Institute, Menoufia University) ;
  • Khalaf, Fatma A. (Department of Clinical Biochemistry, National Liver Institute, Menoufia University) ;
  • Kotb, Sobhy E. (Department of Pediatric Medicine, Ministry of Health Hospital)
  • 투고 : 2018.10.07
  • 심사 : 2019.08.21
  • 발행 : 2020.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Immunomodulatory properties of interferon (IFN) have been documented. It may induce autoimmune diseases such as autoimmune thyroiditis with hypo- or hyperthyroidism. In addition, it may impair thyroid hormone synthesis through affecting iodide organification in thyroid gland. Purpose: The aim of this study was to describe thyroid function tests disturbances in children with chronic hepatitis C (CHC) receiving pegylated interferon-alpha (PEG IFN-α) plus ribavirin. Methods: Fifty children with CHC virus infection who received combined pegylated interferon-alpha with ribavirin were selected. Other 50 apparently healthy children of matched age and sex (considered as control group) were selected. All children (100) were subject to liver function tests, virological studies, and follow-up of thyroid function test during and after the treatment course. Results: Our study showed that 28% of children received combined PEG IFN-α plus ribavirin showed subclinical hypothyroidism. After 24 weeks treatment with combined therapy of IFN plus ribavirin, the mean level of thyroid stimulating hormone (TSH) was 3.23±88 mU/mL, while TSH was 1.16±0.77 mU/mL before starting treatment. On the other hand, mean TSH was 1.09±0.92 mU/mL in normal control group. Conclusion: This study revealed an association between subclinical thyroid dysfunction and treatment with IFN-alpha and ribavirin in children. Further studies on larger number of patients and longer follow-up duration are recommended for further confirmation.

키워드

참고문헌

  1. Iliescu EL, Mercan-Stanciu A, Toma L, Ioanitescu ES, Dumitru R, Rusie D. Hepatocellular carcinoma in the setting of interferon free treatment for chronic HCV hepatitis - experience of a single center. Hepatoma Res 2018;4:3. https://doi.org/10.20517/2394-5079.2017.48
  2. Abd-Elgawad MM, Baddour NM, Salem MA. Chronic hepatitis C in children: clinical spectrum and histopathological study. Alexandria Journal of Medicine 2013;49:363-8. https://doi.org/10.1016/j.ajme.2013.03.008
  3. El-Guindi MA. Hepatitis C viral infection in children: updated review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95. https://doi.org/10.5223/pghn.2016.19.2.83
  4. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012;54:838-55. https://doi.org/10.1097/MPG.0b013e318258328d
  5. Stallings-Smith S, Krull KR, Brinkman TM, Hudson MM, Ojha RP. Longterm follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection. J Clin Virol 2015;71:18-21. https://doi.org/10.1016/j.jcv.2015.07.306
  6. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012;18:99-104. https://doi.org/10.3748/wjg.v18.i2.99
  7. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007;196:1474-82. https://doi.org/10.1086/522608
  8. Wiersinga WM. Guidance in subclinical hyperthyroidism and subclinical hypothyroidism: are we making progress? Eur Thyroid J 2015;4:143-8. https://doi.org/10.1159/000438909
  9. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009;23:703-12. https://doi.org/10.1016/j.beem.2009.07.004
  10. Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005;29:339-45. https://doi.org/10.1016/S0399-8320(05)80778-X
  11. Andrade LJ, Atta AM, D'Almeida Junior A, Parana R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review. Braz J Infect Dis 2008;12:144-8. https://doi.org/10.1590/S1413-86702008000200009
  12. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9. https://doi.org/10.1210/jcem.86.5.7459
  13. Vasiliadis T, Anagnostis P, Nalmpantidis G, Soufleris K, Patsiaoura K, Grammatikos N, et al. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore 2011;40:394-400.
  14. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6. https://doi.org/10.1089/thy.1997.7.891
  15. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, et al. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-31. https://doi.org/10.1530/eje.0.1410325
  16. World Health Organization. Global hepatitis [Internet]. Geneva (Switzerland): World Health Organization, 2007.
  17. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-45. https://doi.org/10.1002/hep.1840360621
  18. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117:10-3. https://doi.org/10.1016/j.amjmed.2004.01.023
  19. Floreani A, Betterle C, Carderi I, Presotto F, Pedini B, Moscon A, et al. Is hepatitis C virus a risk factor for thyroid autoimmunity? J Viral Hepat 2006;13:272-7. https://doi.org/10.1111/j.1365-2893.2005.00699.x